Systemic effects of conjugated equine estrogen vaginal cream on bone turnover markers in postmenopausal women

被引:1
|
作者
Luengratsameerung, S. [1 ]
Panyakhamlerd, K. [1 ]
Treratanachat, S. [2 ]
Taechakraichana, N. [1 ]
机构
[1] Chulalongkorn Univ, Reprod Med Div, Dept Obstet & Gynecol, Menopause Res Unit,Fac Med, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Div Gynecol Pathol, Dept Obstet & Gynecol, Fac Med, Bangkok 10330, Thailand
关键词
CONJUGATED EQUINE ESTROGEN; VAGINAL CREAM; BONE TURNOVER MARKERS; POSTMENOPAUSE; VULVOVAGINAL ATROPHY; HORMONE REPLACEMENT THERAPY; BIOCHEMICAL MARKERS; MINERAL DENSITY; LOCAL ESTROGEN; ESTRADIOL; EFFICACY; CALCIUM; 17-BETA-ESTRADIOL; RALOXIFENE; MANAGEMENT;
D O I
10.3109/13697137.2012.662252
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To evaluate the systemic effect of therapy with conjugated equine estrogen (CEE) vaginal cream on bone turnover markers in postmenopausal women. Methods This study was conducted in 40 spontaneously menopausal women aged 40-60 years who complained of vulvovaginal symptoms. Subjects were instructed to self-administer 1 g CEE vaginal cream (CEE 0.625 mg) once daily for 12 weeks (continuous phase), then twice weekly for the next 12 consecutive weeks (intermittent phase). Serum levels of bone turnover markers and estradiol and the vaginal maturation index were evaluated at baseline, 12 and 24 weeks after treatment initiation. Results Levels of C-terminal cross-linked telopeptide of type I collagen (CTx) were significantly decreased at 12 weeks and 24 weeks when compared to baseline values (median (range) 0.435 (0.171-0.859) and 0.391 (0.122-0.714) vs. 0.562 (0.250-1.290) ng/ml (p < 0.001 and < 0.001), respectively), but there was no significant difference between the levels at 12 and 24 weeks. Levels of procollagen type I N-terminal propeptide (P1NP) and osteocalcin levels were significantly decreased after 24 weeks when compared to pretreatment levels (mean (standard deviation) 41.74 (11.76) vs. 50.02 (17.71) ng/ml (p = 0.002) for P1NP and 23.91 (7.11) vs. 27.54 (8.67) ng/ml (p < 0.001) for osteocalcin, respectively). Estradiol levels were significantly increased and the vaginal maturation index was significantly improved after 12 and 24 weeks when compared to baseline. Conclusions CEE vaginal cream significantly decreased the bone resorption marker (CTx) in postmenopausal women after completion of the continuous-treatment phase. There was no significant further decrease after the intermittent phase. The effects on the markers of bone formation and bone turnover (P1NP and osteocalcin) were apparent only at 24 weeks. The two treatment phases moderately increased serum estradiol levels and significantly improved the vaginal maturation index.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
  • [1] Comparison of Pueraria mirifica gel and conjugated equine estrogen cream effects on vaginal health in postmenopausal women
    Suwanvesh, Narathorn
    Manonai, Jittima
    Sophonsritsuk, Areepan
    Cherdshewasart, Wichai
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (02): : 210 - 215
  • [2] Markers of bone turnover correlate with changes in histomorphometric parameters in postmenopausal women treated with conjugated equine estrogen
    Prestwood, KM
    Gunness, M
    Muchmore, DB
    Lu, Y
    Parfitt, AM
    Raisz, LG
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : 142 - 142
  • [3] A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women
    Reid, IR
    Eastell, R
    Fogelman, I
    Adachi, JD
    Rosen, A
    Netelenbos, C
    Watts, NB
    Seeman, E
    Ciaccia, AV
    Draper, MW
    ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (08) : 871 - 879
  • [4] The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: A comparative study
    Manonai, J
    Theppisai, U
    Suthutvoravut, S
    Udomsubpayakul, U
    Chittacharoen, A
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2001, 27 (05) : 255 - 260
  • [5] Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy
    Parsons, A
    Merritt, D
    Rosen, A
    Heath, H
    Siddhanti, S
    Plouffe, L
    OBSTETRICS AND GYNECOLOGY, 2003, 101 (02): : 346 - 352
  • [6] Bone Turnover Markers in Old and Postmenopausal Women
    Chan, Kien
    Nair, Preeti
    Pang, Wee Yang
    Chauhan, Anupam
    Inderjeeth, Charles
    Lim, Ee Mun
    AUSTRALASIAN JOURNAL ON AGEING, 2014, 33 : 46 - 47
  • [7] Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women
    Dias, A. R., Jr.
    de Mello, N. R.
    Gebara, O. C. Eluf
    Nussbacher, A.
    Wajngarten, M.
    Petti, D. A.
    CLIMACTERIC, 2008, 11 (05) : 390 - 396
  • [8] Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
    Shiraki, M.
    Sugimoto, T.
    Nakamura, T.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 219 - 226
  • [9] Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
    M. Shiraki
    T. Sugimoto
    T. Nakamura
    Osteoporosis International, 2013, 24 : 219 - 226
  • [10] Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
    Janne Komi
    Kari S. Lankinen
    Michael DeGregorio
    Jorma Heikkinen
    Seppo Saarikoski
    Marjo Tuppurainen
    Kaija Halonen
    Risto Lammintausta
    Kalervo Väänänen
    Olavi Ylikorkala
    Risto Erkkola
    Journal of Bone and Mineral Metabolism, 2006, 24 : 314 - 318